INB03 Development Philosophy
Phase I clinical trial in patients with advanced solid tumors with elevated MDSC in their blood
Patients with advance solid tumors (advanced cancer with metastasis) who have elevated number of MDSC in their blood will be eligible. The clinical trial is designed as a standard open label dose-escalation trial using biomarkers for patients selection.
Phase II clinical trial in advanced melanoma patients who are refractory or resistant to CPI and have elevated MDSC in their blood
Patients with advanced melanoma who have been treated with CPI in the past but were found to be resistant to CPI or have developed refractory disease (progression on CPI) who have increased MDSC in their blood will be eligible. The clinical trial will be a Phase II, open label dose escalation trial with two arms, resistant disease and refractory disease. Patients will be treated with INB03 in combination with CPI.